Claims
- 1. A method of reducing or inhibiting wound contraction in a subject, comprising administering to said subject a pharmaceutical composition comprising a peptide having more than three consecutive basic amino acid residues and a pharmaceutically acceptable carrier.
- 2. The method of claim 1, wherein each of said basic amino acid residues independently is selected from the group consisting of arginine, lysine, and ornithine.
- 3. The method of claim 1, wherein said peptide is selected from the group consisting of:
- G-{(D)R}.sub.5 -GGG-(D)R-ADSPASSK; and
- YGRRRRRQRRRP (SEQ ID NO: 1).
- 4. The method of claim 1, wherein said peptide is selected from the group consisting of:
- G-{(D)R}.sub.5 -GGG-(D)R-GDSPASSK;
- G-{(D)R}.sub.5 -GGG-(D)R-GDIPASSK;
- GRRRRGGGRGDIPT (SEQ ID NO: 6);
- RRRRGRGDIPT (SEQ ID NO: 7); and
- GRRRRRGGRGDIPT (SEQ ID NO: 8).
- 5. The method of claim 1, wherein said peptide is selected from the group consisting of:
- G-{(D)R}.sub.5 -GGG;
- RRRR (SEQ ID NO: 9);
- RRRRG (SEQ ID NO: 10); and
- GRRRRRGG (SEQ ID NO: 11).
- 6. A method of reducing or inhibiting wound contraction in a subject, comprising administering to said subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a peptide containing the amino acid sequence arginine-glycine-aspartic acid and a basic amino acid sequence.
- 7. The method of claim 6, wherein said peptide is selected from the group consisting of:
- GRRGRRGRGDT (SEQ ID NO: 12);
- GRRRGGRGDIPT (SEQ ID NO: 13); and
- AcRRRGGRGDIPK (SEQ ID NO: 14).
- 8. A method of reducing or inhibiting wound contraction in a subject, comprising administering to said subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a peptide of six to about thirty amino acid residues containing therein a sequence of six consecutive amino acid residues of which at least about four of said six amino acid residues are basic amino acid residues.
- 9. The method of claim 8, wherein each of said basic amino acid residues independently is selected from the group consisting of arginine, lysine, and ornithine.
- 10. The method of claim 8, wherein said peptide is selected from the group consisting of:
- GRRGRRGRGDT (SEQ ID NO: 12);
- GRRRGGRGDIPT (SEQ ID NO: 13); and
- AcRRRGGRGDIPK (SEQ ID NO: 14).
- 11. The method of claim 8, wherein said peptide is selected from the group consisting of:
- GRRGRR (SEQ ID NO: 15);
- GRRGRRGR (SEQ ID NO: 16);
- GRRRGGR (SEQ ID NO: 17); and
- AcRRRGGR (SEQ ID NO: 18).
Parent Case Info
This application is a continuation-in-part of U.S. Ser. No. 08/234,979, filed Apr. 28, 1994 now U.S. Pat. No. 5,510,328.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5510328 |
Polarek et al. |
Apr 1996 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
9006767 |
Jun 1990 |
WOX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
234979 |
Apr 1994 |
|